Special Issue

Targeted Therapies and Drug Delivery for Neurodegenerative Diseases

Message from the Guest Editors

Neurodegenerative diseases like AD, PD, ALS, MS, and epilepsy are complex and hard to treat due to the blood-brain barrier. But recent advances in targeted therapies and drug delivery systems, such as nanoparticles and gene-based treatments, are bringing hope. This Special Issue calls for papers on innovative strategies, including new drug formulations, advanced delivery platforms, and BBB-targeting mechanisms, to accelerate transformative therapies and improve patient outcomes. We welcome your contributions.

Guest Editors

Dr. Ramona Meanti

Department of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy

Dr. Chiara Lucchi

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41100 Modena, Italy

Deadline for manuscript submissions

28 February 2026



an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



mdpi.com/si/238229

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics





an Open Access Journal by MDPI

Impact Factor 5.5 CiteScore 10.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko

Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

